Welcome to our dedicated page for Affimed news (Ticker: AFMD), a resource for investors and traders seeking the latest updates and insights on Affimed stock.
Affimed N.V. (AFMD) has been a Nasdaq-listed, clinical-stage immuno-oncology company focused on innate cell engagers (ICE®) generated on its proprietary ROCK® platform. Company news has highlighted how these ICE® molecules are being developed to recognize and kill a range of hematologic and solid tumors by engaging innate immune cells.
News coverage for AFMD includes detailed clinical updates on key ICE® programs such as AFM24, AFM28 and acimtamig (AFM13). Releases describe AFM24 as a tetravalent, bispecific ICE® targeting CD16A and EGFR, with data in advanced or metastatic non-small cell lung cancer, including combinations with atezolizumab. For AFM28, Affimed has reported early Phase 1 results in relapsed/refractory acute myeloid leukemia, including composite complete remission rates and safety findings. Additional news has covered acimtamig in combination with AlloNK® (AB-101) in classical Hodgkin lymphoma, with abstracts accepted for major oncology meetings.
Another important category of AFMD news relates to corporate and listing developments. In May 2025, Affimed announced that it had filed for insolvency proceedings in Mannheim, Germany, citing overindebtedness and liquidity concerns. Shortly thereafter, the company disclosed that Nasdaq staff would suspend trading of its common shares and proceed with a delisting process, culminating in a Form 25 filing to remove its common stock from Nasdaq listing and registration.
On this news page, readers can review historical press releases on AFMD’s clinical trial data, conference presentations, investor webcasts, and regulatory and listing updates. For those tracking the company’s ICE® pipeline and its insolvency and delisting process, this archive offers a centralized view of how Affimed’s scientific, clinical, and corporate story has evolved over time.
Affimed N.V. (NASDAQ: AFMD) and NKMax America Inc. announced the FDA's clearance of an IND for a Phase 1/2a study. This trial will explore the combination of AFM24, an EGFR/CD16A innate cell engager, with SNK-01, an autologous NK-cell product, targeting solid tumors expressing EGFR. The aim is to improve treatment outcomes for patients who have failed conventional therapies. The study will assess safety, pharmacokinetics, and preliminary efficacy, marking a significant step for both companies in advancing innate immunity-based therapies.
Affimed N.V. (Nasdaq: AFMD) announced that preclinical data on AFM24 will be showcased via e-poster at the AACR Virtual Annual Meeting I from April 10-15, 2021. The poster presents AFM24 as a potent bispecific innate cell engager targeting EGFR for cancer treatment. Additionally, AFM13 data will be highlighted in a symposium on April 13, focusing on its use in combination with NK cells for treating CD30-expressing lymphomas. These presentations aim to advance understanding of the efficacy of these therapies in oncology.
Affimed N.V. (Nasdaq: AFMD) has decided to continue enrollment in its REDIRECT trial evaluating AFM13 for treating relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL) following a preplanned interim futility analysis. The analysis showed that the response rate in Cohort A qualified for continuation, and Cohorts A and B will merge for further evaluation. Objective responses were observed in heavily pretreated patients with a safety profile consistent with prior trials. An investor conference call is scheduled for March 10, 2021, at 8:30 a.m. EST.
Affimed N.V. (Nasdaq: AFMD) announced a collaboration with Roche to explore AFM24, its innate cell engager, in combination with Roche’s PD-L1 inhibitor atezolizumab for treating patients with advanced solid tumors expressing EGFR. The Phase 1/2a clinical trial will assess safety and efficacy, funded and conducted by Affimed with Roche supplying atezolizumab. This partnership aims to leverage the potential synergistic effects of AFM24 and PD-(L)1 inhibition. Previous studies suggest promising safety and activity profiles for AFM24 in preclinical settings.
Affimed N.V. announced the completion of its public offering of 19,166,667 common shares at a price of $6.00 per share, raising $115 million in gross proceeds. This includes the underwriters' full exercise option for an additional 2,500,000 shares. The offering underlines Affimed's commitment to advancing its immuno-oncology pipeline, which includes therapies for hematologic and solid tumors. Despite the capital raised, potential risks associated with the offering and market conditions remain.
Affimed N.V. (Nasdaq: AFMD) announced the pricing of a public offering of 16,666,667 common shares at $6.00 per share, aiming to raise approximately $94 million after underwriting discounts. The offering includes a 30-day over-allotment option for underwriters to purchase an additional 2,500,000 shares. The proceeds are expected to support the company's clinical-stage immuno-oncology initiatives. The offering is scheduled to close around January 15, 2021, subject to standard conditions.
Affimed N.V. (Nasdaq: AFMD) announced the commencement of an underwritten public offering of common shares on January 12, 2021. The offering is expected to include a 30-day over-allotment option for underwriters to purchase an additional 15% of shares sold. Jefferies, SVB Leerink, and Credit Suisse are serving as joint book-running managers. The offering is contingent on market conditions, and there is uncertainty surrounding its completion or specific terms.
Heidelberg, Germany, January 11, 2021 – Affimed N.V. (Nasdaq: AFMD) announced that CEO Dr. Adi Hoess will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 7:30 a.m. EST. A live webcast of the presentation will be available on Affimed’s website for 30 days post-event. Affimed focuses on immuno-oncology, developing therapies like AFM13 for CD30-positive relapsed/refractory peripheral T cell lymphoma and AFM24 for advanced EGFR-expressing solid tumors. For details, visit Affimed’s investor site.
Affimed N.V. (Nasdaq: AFMD) announced a debt financing agreement with Silicon Valley Bank, offering up to €25 million in term loans. The structure includes €10 million available at closing, and two additional tranches of €7.5 million, contingent on specific milestones. Interest is set at a minimum of 5.5%, with the loan maturing in November 2025. Proceeds will support research and development of Affimed's ICE® molecules and general working capital.
Affimed N.V. (Nasdaq: AFMD) reported progress in its clinical studies for AFM13 and AFM24 as the company aims to advance its immuno-oncology pipeline. CEO Adi Hoess highlighted a robust cash position of approximately €147 million, enabling operations into H1 2023. Key updates include the AFM13-202 trial for CD30-positive T-cell lymphoma, which is ahead of schedule, and the AFM24-101 trial, now in the fourth dose cohort. The company anticipates regulatory submissions and continued clinical development, positioning it well for future growth and innovation.